Out-licensing
Up-to-date access to technology licensing opportunities worldwide.
- Out-licensing
- Browse
Licensing opportunities
25 and 50 mg diclofenac K film coated immediate release tablets More
Apitoxin is a new biological drug for pain & inflammation and arthritis, approved by the Korean FDA on May 3, 2003 after 14 years of preclinical, animal, and phase I, II & III clinical studies More
The First Line of Therapy in Severe Migraine Attacks More
The omega-3 fatty acids are extracted from New Zealand green lipped mussels and developed into oils for use in anti-inflammatory compounds by our UK based clients. More
Proprietary supercritical fluid (SCF) technology to improve bioavailability, enhance stability and optimise drug delivery for small and large molecules in a range of dosage forms. More
Our clients are sourcing and developing unique omega-3 fatty acids from green lipped mussels for the treatment of joints, asthma and dermatitis in animals. More
Supercritical fluid crystal and particle engineering to form particles with strong aerodynamic performance and exceptional size uniformity for optimised pulmonary/nasal delivery More
LT-NS001, is an NSAID pro-drug for the treatment of chronic inflammatory conditions, such as osteoarthritis. Multiple phase I trials demonstrated its safety and proof of concept. More
Related Reports
Market Research Reports provided by reports.iptechex.com
Oct 2010 - 169 pages - $3,500
Nov 2010 - 40 pages - $500
Nov 2010 - 1336 pages - $1,495
Nov 2010 - 205 pages - $1,495
Nov 2010 - 41 pages - $2,000
Dec 2010 - 31 pages - $500
Nov 2011 - 7 pages - $3,835
Nov 2011 - 96 pages - $3,500
Sep 2011 - 74 pages - $500
Your selection
Browse By
© Copyright 1998-2013 IP Technology Exchange, Inc All rights reserved. Terms and Conditions | Contact us